DURECT Reports Data From European Phase IIb Hysterectomy Study of Posidur (SABER-Bupivacaine)
CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR™ (also known as SABER™-bupivacaine...
Short URL: http://drugrehab.in/?p=169
Posted by admin
on Jun 17 2010. Filed under Drug Rehabilation.
You can follow any responses to this entry through the RSS 2.0.
Both comments and pings are currently closed.
